Using a focused epigenetic compound screen across multiple MRT cell lines, we identified that the HDAC inhibitor panobinostat (LBH589) and the BET inhibitor birabresib (OTX015) act synergistically to inhibit cell proliferation, with combination index (CI) values consistently <1. In vivo, this dual-epigenetic targeting significantly attenuated tumor growth in MRT xenograft models, outperforming either monotherapy, and was associated with suppressed proliferation and E2F1 signaling. Our findings unveil a novel synergistic strategy that pharmacologically recapitulates a core SMARCB1-mediated tumor-suppressive circuit, nominating combined HDAC and BET inhibition as a promising therapeutic avenue for MRT.

In conclusion, we identified molecular subtypes of NPC, constructed preliminary diagnostic and prognostic marker panels, and observed the therapeutic potential of Panobinostat, as a monotherapy and in combination with radiotherapy. These findings provide a solid foundation for precision diagnosis, prognostic stratification, and personalized treatment strategies for NPC.

In silico drug screening and molecular docking suggested that the histone deacetylase inhibitor Trichostatin A may hold therapeutic potential. This study provides novel biomarkers and insights for the diagnosis and targeted therapy of pGBM.

YAP is a strong predictive biomarker of response to immunotherapy in NSCLC. The combination of TD and ICIs shows promise in reversing immunotherapy resistance associated with high YAP expression, offering a potential strategy to overcome acquired resistance.

P2, N=69, Recruiting, Rong Tao | Not yet recruiting --> Recruiting

At single-cell resolution, this study characterizes the LMIC population in PDAC and implicates a CAF-associated SEMA3A-NRP1 signaling axis within their spatial and functional microenvironmental niches. These findings provide a refined conceptual framework for the development of prospective targeted strategies aimed at disrupting early microenvironmental cross-talk associated with PDAC liver metastasis.

P2, N=32, Active, not recruiting, Liping Dou

Anti-glioma effects with the lowest drug concentrations were achieved for proteasome inhibitors (carfilzomib, bortezomib, ixazomib), and HDAC inhibitors (panobinostat, romidepsin). The impact of their drug targets PSMB5 and HDAC1/2 on the growth of GBM cells was successfully validated by RNAi experiments. We established an aHTS platform for GBM TOs, and identified proteasome and HDAC inhibitors as promising drugs for the treatment of GBMs.

This study integrated multi-omics data with machine learning to develop a robust four-gene diagnostic model for NPC. The core genes (COL4A2, LAMB1, ACTA2, CCL2) are associated with tumor progression, prognosis, immune regulation, and distinct biological pathways. Our findings provide a valuable tool for the diagnosis and risk stratification of NPC and reveal potential therapeutic targets worthy of further investigation.

P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027

P2, N=73, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2023 --> Oct 2025

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed